The P2X7 receptor, despite disappointing outcomes from early clinical testing of P2X7 receptor antagonists for the treatment of rheumatoid arthritis, remains an attractive therapeutic target, with promising potential in the development of therapeutics for a diversity of debilitating conditions. This evidence concerns the gene P2RX7 and rheumatoid arthritis.